Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')2 fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study-Reference-Cited by-同舟云学术

Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')2 fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study

Published:2015-03 Issue:3 Volume:15 Page:285-292
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Bal Céline,Herbreteau Cécile H,Buchy Philippe,Rith Sareth,Zaid Masliza,Kristanto William,Han Velda,Reynaud Charlotte,Granjard Patrick,Lépine Bertrand,Durand Caroline,Tambyah Paul A

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference33 articles.

1. Avian influenza A (H5N1) in 10 patients in Vietnam;Tran;N Engl J Med,2004

2. Avian influenza A (H5N1) infection in humans;Beigel;N Engl J Med,2005

3. Person-to-person transmission of influenza A (H5N1);Nguyen;Lancet,2008

4. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China;Wang;Lancet,2008

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Passive immunotherapies for the next influenza pandemic;Reviews in Medical Virology;2024-04-18

2. A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)₂ fragments in healthy volunteers;British Journal of Clinical Pharmacology;2024-01-30

3. Preparedness for future outbreaks: strengthening surveillance of survivors of Ebola virus disease;The Lancet Infectious Diseases;2023-11

4. Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab′)2 fragments;Scientific Reports;2023-08-25

5. Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2;Frontiers in Immunology;2022-08-15